

Gregory Pastores

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11526836/publications.pdf>

Version: 2024-02-01

23
papers

1,684
citations

686830

13
h-index

752256

20
g-index

23
all docs

23
docs citations

23
times ranked

1447
citing authors

#	ARTICLE	IF	CITATIONS
1	IMPACT study: measuring the impact of caregiving on families and healthcare professionals of children and adults living with mucopolysaccharidoses in Ireland. <i>Therapeutic Advances in Rare Disease</i> , 2021, 2, 263300402110207.	0.3	2
2	Aberrant progranulin, YKL-40, cathepsin D and cathepsin S in Gaucher disease. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 62-67.	0.5	13
3	The genetic and biochemical basis of trimethylaminuria in an Irish cohort. <i>JIMD Reports</i> , 2019, 47, 35-40.	0.7	5
4	Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. <i>Blood Cells, Molecules, and Diseases</i> , 2019, 77, 101-102.	0.6	1
5	P627â€¦Mitochondrial disease mimics. , 2019, , .		0
6	Presenting signs and patient coâ€¦variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GEDâ€¦) Delphi initiative. <i>Internal Medicine Journal</i> , 2019, 49, 578-591.	0.5	39
7	Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 71, 71-74.	0.6	27
8	Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 68, 47-53.	0.6	45
9	Pharmacological treatment of pediatric Gaucher disease. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1183-1194.	1.3	20
10	Outcomes after 18 months of eliglustat therapy in treatmentâ€¦naïve adults with <scp>G</scp>aucher disease type 1: The phase 3 ENGAGE trial. <i>American Journal of Hematology</i> , 2017, 92, 1170-1176.	2.0	77
11	Spotlight on taliglucerase alfa in the treatment of pediatric patients with type 1 Gaucher disease. <i>Pediatric Health, Medicine and Therapeutics</i> , 2017, Volume 8, 73-81.	0.7	4
12	PO099â€¦Autosomal dominant gene negative frontotemporal dementia-think sca17. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, A37.4-A38.	0.9	0
13	Clinical course of sly syndrome (mucopolysaccharidosis type VII). <i>Journal of Medical Genetics</i> , 2016, 53, 403-418.	1.5	133
14	Association Between Progranulin and Gaucher Disease. <i>EBioMedicine</i> , 2016, 11, 127-137.	2.7	72
15	Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 695.	3.8	120
16	High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease. <i>Journal of Inherited Metabolic Disease</i> , 2010, 33, 291-300.	1.7	47
17	Genz-112638 for Gaucher Disease Type 1: Phase 2 Clinical Trial Results After 18 Months of Treatment.. <i>Blood</i> , 2009, 114, 1349-1349.	0.6	3
18	Management of patients with Gaucher's disease: Clinical perspectives. <i>European Journal of Internal Medicine</i> , 2006, 17, S9-S12.	1.0	1

#	ARTICLE	IF	CITATIONS
19	Miglustat: Substrate Reduction Therapy for Lysosomal Storage Disorders Associated with Primary Central Nervous System Involvement. <i>Recent Patents on CNS Drug Discovery</i> , 2006, 1, 77-82.	0.9	20
20	Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. <i>Journal of Pediatrics</i> , 2004, 144, 112-120.	0.9	107
21	Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. <i>American Journal of Medicine</i> , 2002, 113, 112-119.	0.6	491
22	The Gaucher Registry. <i>Archives of Internal Medicine</i> , 2000, 160, 2835.	4.3	451
23	Scintigraphic evaluation of Tc ^{99m} low-density lipoprotein (LDL) distribution in patients with Gaucher disease. <i>Clinical Genetics</i> , 1997, 52, 7-11.	1.0	6